A Case of Phlegmasia Cerulea Dolens in a Patient With COVID-19, Effectively Ttreated With Fasciotomy and Mechanical Thrombectomy

Ann Vasc Surg. 2022 Feb:79:122-126. doi: 10.1016/j.avsg.2021.07.034. Epub 2021 Oct 10.

Abstract

Coronavirus disease 2019 (COVID-19) has been widely reported to be associated with increased risk of Venous Thromboembolism, both deep vein thrombosis (DVT) and pulmonary embolism. A rare and extreme manifestation of DVT is Phlegmasia cerulea dolens, characterized by poor tissue perfusion due to marked limb swelling which can progress to limb and life-threatening venous gangrene. We report the case of a 53-year-old man with severe SARS-CoV2 pneumonia who developed acute iliofemoral DVT leading to acute limb ischemia due to Phlegmasia cerulea dolens. The patient underwent successful emergent fasciotomy and mechanical thrombectomy with removal of extensive thrombus burden and restoration of normal venous circulation. Our case highlights the importance of clinical vigilance and early implementation of therapeutic interventions to avoid adverse outcomes in patients who develop SARS-CoV2 induced Venous Thromboembolism complications.

Keywords: COVID-19; Deep Vein Thrombosis (DVT); Dolens (PCD); Mechanical Thrombectomy; Phlegmasia Cerulean; SARS-CoV2.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / therapeutic use
  • COVID-19 / complications
  • COVID-19 / diagnosis
  • COVID-19 / therapy*
  • Fasciotomy*
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Thrombectomy*
  • Thrombophlebitis / diagnosis
  • Thrombophlebitis / etiology
  • Thrombophlebitis / surgery*
  • Treatment Outcome
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / surgery*

Substances

  • Anticoagulants